MedTrace Logo

ANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB)

NCT05773443 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-03-17

No results posted yet for this study

Summary

The goal of the study is to develop predictive algorithms and digital biomarkers to capture disease fluctuations in (prodromal) dementia with lewybodies (DLB) patients and to improve treatment, diagnosis and prognosis of the study drug Ambroxol, used in the ANeED study. This project is an additional study to the ANeED study, registered at ClinicalTrials.gov under NCT04588285.

Conditions

  • Dementia, Lewy Body

Interventions

DEVICE

Digital biomarkers

Digital application Smartwatch Sleep monitor Movement sensor EEG-sensor

Sponsors & Collaborators

  • Helse Fonna

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • University Hospital, Akershus

    collaborator OTHER

  • Ullevaal University Hospital

    collaborator OTHER

  • Haraldsplass Deaconess Hospital

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • University of Bergen

    lead OTHER

Principal Investigators

  • Arvid Rongve, PhD · University of Bergen / Helse Fonna

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05773443 on ClinicalTrials.gov